Clinical Professionals

Experienced

Our team consists of highly qualified and experienced clinical professionals who make sure each and every exceptional patient is taken care of every step of the way before, during, and in follow up.

Why PRC?

From start of finish, PRC provides an unparalleled level of experience and professionalism throughout the clinical trial process.

Our Team

Our experienced staff will guide you through the clinical trial process. From start to finish, PRC is dedicated to providing the best experience for our study patients.

About us

Study Information

Read about the studies that PRC takes part in, upcoming studies, and study information.

Current Studies

Innovative Clinical Solutions

Availability

At PRC we understand your time is important. Our staff will schedule appointments to accommodate your availability. Communication is key to the success of our patients and sponsors, we are available and provide prompt response via telephone, email and text messaging.

Knowledge

PRC partners with experienced and dedicated practicing neurologists, primary care providers, and other advanced practitioners to help provide a review of medicine and progress in patient care for various medical conditions

Experience

Perseverance Research Center’s research professionals have been conducting clinical research in Arizona for over 40 years and have a known reputation for excellence, quality and consistency. 

Enrolling Studies

Studies

Dementia/Alzheimer’s Disease

Eligible patients between 55-80 years of age who meet the criteria for probable AD dementia.

Alzheimer’s disease is the leading neurodegenerative disorder in the world today, and accounts for over 65% of all cases of dementia. It is estimated that the prevalence of AD across all age groups in the US was 5.8 million individuals in 2020. It currently affects one in ten people aged 65 and older. This number will grow each year in the US as the size and proportion of the population age 65 and older continues to increase.

To date, most AD therapeutics have focused on a single target which belies the multifactorial systems biology nature of the disease. System biology agents that target the regenerative system of the brain while simultaneously targeting mechanisms involved in generation of AD pathology have the potential to prevent and/or delay AD in those at greatest risk.

PRC is working with admirable, experienced neurologists to help advance the development of new, effective regenerative therapeutics for AD.

Multiple Sclerosis (RRMS and SPMS)

Eligible patients between 18-60 years old diagnosed with multiple sclerosis (RMS, RRMS, SPMS)

MS is a chronic, immune-mediated disorder of the central nervous system characterized by inflammation, demyelination, and axonal damage leading to progressive neurological impairment and disability.

Relapsing Multiple Sclerosis (RMS) is the most common form of MS, accounting for about 85% of cases and includes Relapsing-Remitting MS (RRMS) and Secondary Progressive MS (SPMS). RRMS is characterized by well-defined relapses with partial or complete recovery, while SPMS, which may develop after RRMS, is marked by continuous disability progression with or without acute relapses.

In collaboration with world-renowned MS specialists, PRC offers several immunomodulatory therapies that can be highly effective in MS.

Pediatric Migraines

Eligible patients between 6-17 years old at time of screening who have a history of migraine attacks for at least 6 months. Reports at least 2 and no more than 8 moderate-to-severe migraine attacks per month.

Headaches are very common in children and teens. In fact, more than half will suffer from headaches at some point, and by 18 years the majority of adolescents have had them.

And while most headaches are part of a viral illness, some are migraines. In fact, recurring migraines affect as many as one in 10 children and teens overall and more than half of pediatric patients with migraines have 1 to 4 attacks per month, causing interference with their daily activities of life.

PRC is working with the best migraine specialists to help your children prevent and mitigate the pain they experience during a migraine.

Pediatric Epilepsy

Eligible patients between 1-17 years old at the time of screening who have an established diagnosis of focal or generalized epilepsy.

Epilepsy in children is a brain condition that causes seizures. The cells in your child’s brain create a sudden burst of irregular electrical activity and a seizure is the result. You may recognize a seizure when someone passes out and their body shakes uncontrollably. But not all seizures look the same. Some children may stare or experience confusion during a seizure. Epilepsy affects every child/adolescent differently depending on their age, the type of seizures they have, and how they respond to epilepsy treatment. Some children and youth can easily keep their seizures under control by taking seizure medicine and may outgrow their seizures. Others may have cases that are more difficult to manage and require lifelong treatment.

PRC with the help of experienced pediatric epileptologists, are working with several pharmaceutical companies to decrease the severity and frequency of your child’s epilepsy.

Narcolepsy

Eligible patients between 18 to 65 years with narcolepsy (NT1 and NT2) and IH

Excessive daytime sleepiness (EDS) is a common medical problem.

People with EDS may have decreased alertness and attention when they are at school, working, driving, or performing other activities of daily living.

EDS is associated with a wide range of diseases, including sleep, metabolic, cardiovascular, neurological, and psychiatric disorders.

Disorders of EDS include rare but severe disorders of central hypersomnia, such as narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic

hypersomnia (IH).

PRC is collaborating with Arizona’s most prestigious comprehensive sleep medicine center to provide patients with long-term sleep medicine care for chronic conditions including insomnia, sleep apnea, restless legs syndrome, periodic limb movement disorder, and narcolepsy.

Diabetic Foot Ulcers

Eligible patients >18 years of age who have an ongoing diagnosis of Diabetes Type 1 or 2, and have a diabetic ulcer of the foot.

Diabetes affects over 500 million people worldwide, representing a significant global health challenge. Certain lifestyle factors not only increase the likelihood of developing diabetes, but also exacerbate its complications. Among these complications, diabetic foot ulcers (DFUs) are especially common. DFUs can result from a variety of factors, including increased pressure on weightbearing areas of the foot, friction due to poorly fitting shoes, gait abnormalities, or sustained injuries. These chronic wounds affect between 1 and 4% of diabetic patients leading to a notable decrease in their quality of life.

The severe impact of DFUs is emphasized by the alarming prognosis associated with them. Patients with DFUs have a high mortality rate which highlights the need to address this complication effectively.

PRC, with the help of local experienced podiatrists, are utilizing different treatments that can aid in surgical closure, enhance functional outcomes, and improve the appearance and recovery time of such wounds

Osteomyelitis

Eligible patients >18 years old with an ongoing diagnosis of Diabetes Type 1 or 2, who have a confirmed presence of diabetic foot osteomyelitis (DFO) of the forefoot.

Foot infections are a common, complex, and costly problem in people with diabetes mellitus. Foot infections usually begin in the soft tissue, but may spread contiguously to underlying bone, causing osteomyelitis.

The presence of osteomyelitis is problematic in the management of diabetic foot infections because it is more difficult to treat than soft tissue infections.

PRC, with the help of local experienced surgical podiatrists, are treating patients with a localized agent that is placed directly at the site of infection.

Such treatment can aid in surgical closure, enhance functional outcomes, and improve the appearance and recovery time of such wounds

Weight Loss

Eligible patients ≥18 years of age with a BMI ≥30.0 kg/m2 , or ≥27.0 kg/m2 and previously diagnosed with or receiving treatment for at least 1 of the following weight-related comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease

In 2023, the obesity rate in the United States was 40.3% for adults aged 20 and older. The World Obesity Federation predicts that by 2025, 2.7 billion adults could be living with overweight or obesity, making it a global health challenge and placing a high burden on individuals, healthcare systems, and society.

Overweight and obesity are complex chronic conditions involving abnormal or excessive fat accumulation that presents a risk to a person’s overall health.

PRC is studying an oral glucagon/GLP-1 receptor dual agonist that activates both the GLP-1 and glucagon receptors, which are critical to controlling metabolic functions.

Mild Cognitive Impairment

Eligible patients between 55-90 years of age with memory issues

Mild cognitive impairment (MCI) is a condition in which people have more memory or thinking problems than other people their age. The symptoms of MCI are not as severe as those of Alzheimer’s disease or a related dementia. People with MCI can usually take care of themselves and carry out their normal daily activities. People with MCI are at a greater risk of developing Alzheimer’s disease or a related dementia; however, in many cases, MCI may not ever develop dementia.

PRC is conducting a few clinical trials that could promote neurogenesis, remove misfolded and aggregated proteins and decrease neuroinflammation.

Please contact us for more information

PERSEVERANCE RESEARCH CENTER

CLINICAL RESEARCH + EDUCATION